Reuters
16 Nov 2026, 12:19 UTC · 13h ago
Lilly to buy Calytrix Bio for up to $1.5 billion
Impact · against what's priced in
The acquisition of Calytrix Bio for $1.5 billion is a marginal catalyst for Eli Lilly as it primarily serves to bolster a pipeline the market has not yet fully valued. While it expands the portfolio, the deal size is small relative to Lilly's scale and does not materially shift the growth trajectory required by the current price.
- LLY+0.10
Challenges what's priced in
- The price assumes
The next-generation pipeline... which is unpriced
The market is currently not paying for the next-generation pipeline; adding Calytrix Bio for $1.5 billion provides a incremental boost to this unpriced asset base.
What LLY's price assumes · Sep 10

Search tags




